|Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results|
Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016
Conference call scheduled for
Quarterly and Recent Highlights
VTP-38543 in Atopic Dermatitis
VTP-43742 in Autoimmune Disorders
VTP-45489 in Autoimmune Disorders
New Contour® Program
Expected Upcoming Events
Company to Host Conference Call
Vitae will host a conference call with slides today,
A live audio webcast of the call and accompanying slides will be available via the “Investor Relations” page of the Vitae website, www.vitaepharma.com. Please log on through Vitae’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast and accompanying slides will be archived on Vitae’s website for 90 days following the call.
For additional information, please visit the company’s website at www.vitaepharma.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, the development of Vitae’s clinical programs. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Vitae’s
In addition to the risks described above and in Vitae’s other filings with the